BPCR — Biopharma Credit Balance Sheet
0.000.00%
Last trade - 00:00
- $1.09bn
- $1.00bn
- $135.73m
- 70
- 78
- 51
- 77
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 297 | 193 | 94.7 | 121 | 86.2 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 16.2 | 0.208 | 10 | 19.8 | 20.3 |
Total Other Current Assets | |||||
Total Current Assets | 313 | 193 | 105 | 140 | 155 |
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Total Assets | 1,429 | 1,388 | 1,371 | 1,364 | 1,357 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 24.5 | 9.39 | 6.34 | 26.3 | 15.9 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 25.2 | 9.39 | 6.9 | 26.6 | 15.9 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 1,404 | 1,379 | 1,364 | 1,337 | 1,341 |
Total Liabilities & Shareholders' Equity | 1,429 | 1,388 | 1,371 | 1,364 | 1,357 |
Total Common Shares Outstanding |